What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Statistics
His main research concerns Internal medicine, Breast cancer, Oncology, Clinical trial and Cancer.
He combines topics linked to Surgery with his work on Internal medicine.
His Breast cancer research includes elements of Gynecology and Paclitaxel, Chemotherapy.
His research investigates the connection between Chemotherapy and topics such as Tamoxifen that intersect with problems in Regimen.
His Oncology study incorporates themes from Stage, Pathology, Proportional hazards model, Biomarker and Survival analysis.
His Clinical trial research incorporates elements of Research design, Randomized controlled trial, Data mining and Personalized medicine.
His most cited work include:
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 (1248 citations)
- Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer (1093 citations)
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer (975 citations)
What are the main themes of his work throughout his whole career to date?
Donald A. Berry mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Clinical trial.
His research on Internal medicine often connects related areas such as Surgery.
His work in Oncology covers topics such as Biomarker which are related to areas like Bioinformatics.
The concepts of his Breast cancer study are interwoven with issues in Stage, Gynecology and Paclitaxel.
His Cancer research is multidisciplinary, relying on both Proportional hazards model and Disease.
His study looks at the relationship between Clinical trial and topics such as Bayesian probability, which overlap with Econometrics.
He most often published in these fields:
- Internal medicine (49.67%)
- Oncology (46.15%)
- Breast cancer (40.22%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (49.67%)
- Oncology (46.15%)
- Breast cancer (40.22%)
In recent papers he was focusing on the following fields of study:
Donald A. Berry mostly deals with Internal medicine, Oncology, Breast cancer, Cancer and Neoadjuvant therapy.
His work in Trastuzumab, Randomized controlled trial, Lapatinib, Confidence interval and Paclitaxel are all subfields of Internal medicine research.
His research integrates issues of Clinical endpoint, Clinical trial, Chemotherapy, Meta-analysis and Hazard ratio in his study of Oncology.
His study in the fields of MammaPrint under the domain of Breast cancer overlaps with other disciplines such as Olaparib.
The various areas that Donald A. Berry examines in his Cancer study include Regimen and Cohort.
Donald A. Berry has researched Neoadjuvant therapy in several fields, including Stage, Translational research, Melanoma and Clinical study design.
Between 2017 and 2021, his most popular works were:
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA (130 citations)
- Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012 (91 citations)
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial (90 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Statistics
Donald A. Berry mainly investigates Internal medicine, Oncology, Breast cancer, Neoadjuvant therapy and Randomized controlled trial.
As part of his studies on Internal medicine, he frequently links adjacent subjects like Anus.
His Oncology study combines topics from a wide range of disciplines, such as Clinical endpoint, Clinical trial, Confirmatory trial, Trastuzumab and Hazard ratio.
Breast cancer is the subject of his research, which falls under Cancer.
Donald A. Berry interconnects Lapatinib, Melanoma, Anal cancer and Systemic therapy in the investigation of issues within Neoadjuvant therapy.
His study focuses on the intersection of Randomized controlled trial and fields such as Triple-negative breast cancer with connections in the field of Carboplatin, Long term outcomes, Bevacizumab, Chemotherapy regimen and Pembrolizumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
